The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to cause significant morbidity and mortality worldwide. COVID-19 symptoms, including systemic inflammatory response and multi-system organ failure, are now affecting thousands of SARS-CoV-2–infected patients and causing widespread mortality. Life-threatening “cytokine storms” involving the release of pro-inflammatory cytokines (e.g., tumor necrosis factor-α; interleukin-6, -1, and -8; and monocyte chemoattractant protein-1) may contribute to the rapid systemic organ failure observed in select critically ill COVID-19 patients. Therefore, controlling inflammatory responses to COVID-19 may be as important as anti-viral therapies. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production—a process collectively termed the resolution of inflammation. The role of resolution of inflammation in COVID-19 remains of interest. Mortality due to COVID-19 is strongly associated with cardiovascular disease, whereas COVID-19 itself can also induce myocardial injury, acute coronary syndrome, and venous thromboembolism.
Panelists: Dr. Dipak Panigraphy, Dr. Pilar Alcaide, and Dr. Charles Serhan
Moderator: Dr. Chhavi Chauhan